Cantor Fitzgerald Starts Flex Pharma (FLKS) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
JMP Securities Starts Flex Pharma (FLKS) at Market Outperform
February 23, 2015 7:34 AM ESTJMP Securities initiated coverage on Flex Pharma (NASDAQ: FLKS) with a Market Outperform rating and a price target of $30.00.
For an analyst ratings summary and ratings history on Flex Pharma click here. For more ratings news on Flex Pharma click here.
Shares of Flex Pharma closed at $14.71 yesterday.
... MoreRoth Capital Starts Flex Pharma (FLKS) at Buy
February 23, 2015 7:33 AM ESTRoth Capital initiated coverage on Flex Pharma (NASDAQ: FLKS) with a Buy rating and a price target of $27.00.
For an analyst ratings summary and ratings history on Flex Pharma click here. For more ratings news on Flex Pharma click here.
Shares of Flex Pharma closed at $14.71 yesterday.
... MoreJefferies Starts Flex Pharma (FLKS) at Buy
February 23, 2015 7:15 AM ESTJefferies initiates coverage on Flex Pharma (NASDAQ: FLKS) with a Buy rating and a price target of $25.00.
Analyst Ryan Martins comments, "FLKS' proprietary formulation of transient receptor potential (TRP) ion channel activators is well positioned to address muscle cramps and other neuromuscular... More
Piper Jaffray Starts Flex Pharma (FLKS) at Overweight; Sees ~70% Upside
February 23, 2015 6:50 AM ESTPiper Jaffray initiates coverage on recent IPO Flex Pharma (NASDAQ: FLKS) with a Overweight rating and a price target of $25.00.
Analyst Joshua Schimmer commented, "We are initiating coverage of Flex Pharma with an OW rating and $25 PT, representing ~70% upside from... More
